Transgenic Non-Human Animals Producing Modified Heavy Chain-Only Antibodies
Summary
USPTO published patent application US20260090529A1 disclosing transgenic non-human animals that produce modified heavy chain-only antibodies (HCAbs). The invention involves substituting the native amino acid residue at the first position of framework region FR4 with a different residue to disrupt a surface-exposed hydrophobic patch, potentially improving antibody characteristics. Named inventors include Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, and Mike Osborn.
What changed
USPTO published patent application US20260090529A1 for transgenic non-human animals producing modified heavy chain-only antibodies. The application claims animals genetically modified to produce HCAbs where the native amino acid at position one of FR4 is substituted with a different residue capable of disrupting a surface-exposed hydrophobic patch. The application (No. 19393163) was filed November 18, 2025, and published April 2, 2026, covering CPC classifications spanning A01K (transgenic animals) and C07K (peptides/proteins including antibody frameworks C07K 2317/21 through C07K 2317/569).
This patent application does not impose compliance obligations on regulated entities. Biotechnology and pharmaceutical companies developing antibody therapeutics should monitor this application to assess potential licensing implications or freedom-to-operate considerations for similar HCAb engineering approaches. Researchers and developers working with heavy chain-only antibody platforms should review the specific FR4 modifications claimed to understand the scope of protected modifications.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES
Application US20260090529A1 Kind: A1 Apr 02, 2026
Inventors
Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, Mike Osborn
Abstract
Human or chimeric heavy chain-only antibodies are provided, in the native amino acid residue at the first position of the fourth framework region (FR4) of said HCAb is substituted by a different amino acid residue that is capable of disrupting a surface-exposed hydrophobic patch comprising or associated with the native amino acid residue at that position.
CPC Classifications
A01K 67/0275 A01K 67/027 C07K 16/00 A01K 2217/052 A01K 2227/105 A01K 2267/01 C07K 2317/21 C07K 2317/24 C07K 2317/52 C07K 2317/522 C07K 2317/565 C07K 2317/567 C07K 2317/569 C12N 15/902
Filing Date
2025-11-18
Application No.
19393163
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.